Biolyst › ARDXARDELYX, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on October 15, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.
Cash runway is approximately 26.2 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 27 concluded trials, 96% reached completion rather than being terminated or withdrawn.
Track ARDX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open ARDX in the tracker
Recent history
Date Event Type Phase
August 20, 2026
Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years Trial Milestone
Phase 3
August 17, 2026
8-K filed: Other event Filing
—
August 6, 2026
Quarterly results filed (8-K) Earnings
—
July 7, 2026
4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs Trial Milestone
Phase 2
June 17, 2026
8-K filed: Leadership change Corporate
—
April 30, 2026
Quarterly results filed (8-K) Earnings
—
February 19, 2026
Quarterly results filed (8-K) Earnings
—
January 8, 2026
Quarterly results filed (8-K) Earnings
—
December 17, 2025
8-K filed: Leadership change, Other event Corporate
—
October 30, 2025
Quarterly results filed (8-K) Earnings
—
October 14, 2025
8-K filed: Leadership change Corporate
—
August 4, 2025
Quarterly results filed (8-K) Earnings
—
July 3, 2025
8-K filed: Material agreement Corporate
—
June 18, 2025
8-K filed: Leadership change Corporate
—
May 1, 2025
Quarterly results filed (8-K) Earnings
—
April 29, 2025
8-K filed: Leadership change Corporate
—
May 30, 2024
An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females Trial Milestone
Phase 1
December 28, 2021
A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia Trial Milestone
Phase 2
October 13, 2021
Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia Trial Milestone
Phase 4
June 26, 2021
A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP Trial Milestone
Phase 4
November 15, 2019
A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis Trial Milestone
Phase 3
July 17, 2019
Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy Trial Milestone
Phase 2/Phase 3
October 15, 2017
A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C Trial Milestone
Phase 3
August 15, 2017
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C Trial Milestone
Phase 3
May 15, 2017
A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia Trial Milestone
Phase 2
March 15, 2017
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C Trial Milestone
Phase 3
December 15, 2016
An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD) Trial Milestone
Phase 3
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.